Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $49.00 at Guggenheim

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price upped by Guggenheim from $46.00 to $49.00 in a research report released on Monday morning, MarketBeat.com reports. Guggenheim currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Bank of America raised their target price on Tarsus Pharmaceuticals from $42.00 to $54.00 in a report on Wednesday, July 26th. HC Wainwright cut their price objective on Tarsus Pharmaceuticals from $50.00 to $42.00 and set a buy rating on the stock in a report on Friday, August 11th. Finally, William Blair started coverage on Tarsus Pharmaceuticals in a report on Tuesday, July 18th. They set an outperform rating and a $44.00 price objective on the stock.

Tarsus Pharmaceuticals Trading Up 5.8 %

Shares of TARS stock opened at $16.98 on Monday. The stock’s fifty day moving average price is $18.06 and its two-hundred day moving average price is $16.27. The company has a market cap of $553.84 million, a PE ratio of -5.02 and a beta of 0.76. Tarsus Pharmaceuticals has a fifty-two week low of $11.33 and a fifty-two week high of $25.25. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.43 and a current ratio of 12.43.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Thursday, August 10th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.09). Equities analysts predict that Tarsus Pharmaceuticals will post -4.79 EPS for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 103,900 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $20.01, for a total transaction of $2,079,039.00. Following the transaction, the chief executive officer now directly owns 910,106 shares of the company’s stock, valued at approximately $18,211,221.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Tarsus Pharmaceuticals news, insider Aziz Mottiwala sold 2,400 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $20.05, for a total transaction of $48,120.00. Following the transaction, the insider now directly owns 45,806 shares of the company’s stock, valued at approximately $918,410.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 103,900 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $20.01, for a total value of $2,079,039.00. Following the completion of the transaction, the chief executive officer now directly owns 910,106 shares of the company’s stock, valued at $18,211,221.06. The disclosure for this sale can be found here. Insiders have sold a total of 140,300 shares of company stock valued at $2,737,409 in the last 90 days. 11.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its position in Tarsus Pharmaceuticals by 51.0% in the 2nd quarter. BlackRock Inc. now owns 2,199,753 shares of the company’s stock valued at $39,750,000 after buying an additional 742,493 shares in the last quarter. Cowen AND Company LLC bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $36,129,000. Vanguard Group Inc. increased its position in Tarsus Pharmaceuticals by 42.7% in the 3rd quarter. Vanguard Group Inc. now owns 935,649 shares of the company’s stock valued at $16,018,000 after buying an additional 279,826 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $6,535,000. Finally, Geode Capital Management LLC increased its position in Tarsus Pharmaceuticals by 27.4% in the 2nd quarter. Geode Capital Management LLC now owns 444,861 shares of the company’s stock valued at $8,039,000 after buying an additional 95,712 shares in the last quarter. 70.02% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.